Literature DB >> 34159518

A case of lymphomatoid granulomatosis with central nervous system involvement successfully treated with IFNα.

Yoshitaka Yamasaki1, Satoshi Morishige2, Satoru Komaki3, Takuya Furuta4, Hiroshi Koga5, Shuki Oya1, Takayuki Nakamura1, Maki Yamaguchi1, Kazutoshi Aoyama1, Fumihiko Mouri1, Koichi Osaki1, Takekuni Nakama5, Koichi Ohshima4, Motohiro Morioka3, Koji Nagafuji1.   

Abstract

Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease affecting mainly extranodal sites such as the lung, central nervous system (CNS), skin, kidney, and liver. We report a case of low-grade LYG involving the CNS that was successfully treated with interferon alpha (IFNα). A 69-year-old woman developed necrotic erythema of the skin and was initially diagnosed with pyoderma gangrenosum based on skin biopsy. She showed a limited response to prednisolone. Approximately 6 months after the initial onset, low-grade LYG was diagnosed after detection of CNS lesions on brain biopsy. The whole blood EBV-DNA load determined by real-time polymerase chain reaction was slightly elevated. Two months into IFNα therapy, skin and CNS lesions had responded favorably and the EBV-DNA load decreased. IFNα plays an important role in treatment of LYG through its antiproliferative, immunomodulatory, and anti-EBV effects. To our knowledge, this is the first case report of successful treatment with IFNα in Japan. Further investigation is necessary to determine optimal use of IFNα for LYG.

Entities:  

Keywords:  Central nervous system; Epstein–Barr virus; Interferon alpha; Lymphomatoid granulomatosis

Year:  2021        PMID: 34159518     DOI: 10.1007/s12185-021-03178-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  1 in total

1.  Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: lesions with Epstein-Barr virus infection.

Authors:  A K Haque; J L Myers; S D Hudnall; B B Gelman; R V Lloyd; D Payne; M Borucki
Journal:  Mod Pathol       Date:  1998-04       Impact factor: 7.842

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.